The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study

In older patients with acute myeloid leukemia (AML), the definition of fitness, prognosis, and risk of death represents an open question.

[1]  B. Ebert,et al.  Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel. , 2022, Blood.

[2]  H. Döhner,et al.  Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia. , 2022, The New England journal of medicine.

[3]  H. Dombret,et al.  Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy. , 2021, Blood.

[4]  J. Cortes,et al.  Determination of fitness and therapeutic options in older patients with acute myeloid leukemia , 2020, American journal of hematology.

[5]  M. Othus,et al.  Accuracy of SIE/SIES/GITMO Consensus Criteria for Unfitness to Predict Early Mortality After Intensive Chemotherapy in Adults With AML or Other High-Grade Myeloid Neoplasm. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  A. Letai,et al.  Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. , 2020, The New England journal of medicine.

[7]  B. Ebert,et al.  Clonal Hematopoiesis and Measurable Residual Disease Assessment in Acute Myeloid Leukemia. , 2020, Blood.

[8]  Versione,et al.  Common Terminology Criteria for Adverse Events , 2020, Definitions.

[9]  C. Dinardo,et al.  How I treat acute myeloid leukemia in the era of new drugs. , 2019, Blood.

[10]  Yong-mei Zhu,et al.  Genetic alteration patterns and clinical outcomes of elderly and secondary acute myeloid leukemia , 2019, Hematological oncology.

[11]  G. Abel,et al.  Gait speed, grip strength and clinical outcomes in older patients with hematologic malignancies. , 2019, Blood.

[12]  C. Sieber,et al.  Changes of a frailty index based on common blood and urine tests during a hospital stay on geriatric wards predict 6-month and 1-year mortality in older people , 2019, Clinical interventions in aging.

[13]  K. Loh,et al.  Geriatric Assessment in Older Patients with Acute Myeloid Leukemia , 2018, Cancers.

[14]  L. Möllgård,et al.  Acute myeloid leukemia in very old patients , 2018, Haematologica.

[15]  W. Hiddemann,et al.  Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older , 2018, Haematologica.

[16]  E. Estey,et al.  Development and Validation of a Novel Acute Myeloid Leukemia–Composite Model to Estimate Risks of Mortality , 2017, JAMA oncology.

[17]  Bob Löwenberg,et al.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.

[18]  A. Rao.  Fitness in the elderly: how to make decisions regarding acute myeloid leukemia induction. , 2016, Hematology. American Society of Hematology. Education Program.

[19]  S. Kritchevsky,et al.  Effect of Intensive Chemotherapy on Physical, Cognitive, and Emotional Health of Older Adults with Acute Myeloid Leukemia , 2016, Journal of the American Geriatrics Society.

[20]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[21]  H. Wildiers,et al.  International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Gobbi,et al.  Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making , 2013, Leukemia.

[23]  G. Ehninger,et al.  Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Williamson,et al.  Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. , 2010, Blood.

[25]  H. Dombret,et al.  Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  M. Sorror,et al.  Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. , 2005, Blood.

[27]  S. Isom,et al.  Comorbidity, age, and mortality among adults treated intensively for acute myeloid leukemia (AML). , 2016, Journal of geriatric oncology.

[28]  H. Kantarjian,et al.  Acute myeloid leukemia , 2018, Methods in Molecular Biology.